Chembio Diagnostics, Inc.
CEMI · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.18 | -0.05 | -0.11 |
| FCF Yield | -264.96% | -118.20% | -25.43% | -16.63% |
| EV / EBITDA | -0.84 | -1.18 | -4.83 | -7.12 |
| Quality | ||||
| ROIC | -47.65% | -39.85% | -40.50% | -24.29% |
| Gross Margin | 20.19% | 6.58% | 21.60% | 35.02% |
| Cash Conversion Ratio | 0.55 | 0.91 | 0.74 | 0.66 |
| Growth | ||||
| Revenue 3-Year CAGR | 16.65% | 2.33% | -3.04% | 12.80% |
| Free Cash Flow Growth | 56.80% | -42.03% | -79.34% | 3.03% |
| Safety | ||||
| Net Debt / EBITDA | -0.47 | 0.14 | -0.12 | -0.61 |
| Interest Coverage | -53.41 | -8.24 | -7.72 | -0.01 |
| Efficiency | ||||
| Inventory Turnover | 5.00 | 2.67 | 1.91 | 2.33 |
| Cash Conversion Cycle | 182.74 | 167.84 | 144.27 | 143.97 |